Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects.
Sungpil HanHee Youn ChoiYo Han KimJi Yeon NamBongtae KimGeun Seog SongHyeong-Seok LimKyun-Seop BaePublished in: Alimentary pharmacology & therapeutics (2019)
Tegoprazan was well tolerated and showed rapid and potent gastric acid suppression. This supports the further development of tegoprazan as a treatment for acid-related disorders.